OR-AIRSHIP
7.4.2022 10:02:06 CEST | Business Wire | Press release
Airship , the mobile app experience company, today announced the launch of its App Experience Platform (AXP), the only enterprise SaaS platform focused on helping brands master the full lifecycle of mobile app experience (MAX) management. AXP aims to address the ongoing challenge for brands to treat their apps as a high-value destination rather than simply a promotional messaging channel.
Mobile apps have become the centre of the digital customer experience — generating more than three times greater revenue and transaction frequency compared to other channels. Yet, according to data derived from Apptopia, app user retention rates have barely increased over the last three years, despite ongoing growth in annual worldwide app downloads.
AXP enables product, digital and marketing teams to create, refine and publish no-code native app experiences on their own without ongoing developer support or app updates. As a result, it vastly improves the continuous onboarding, retention and first party and zero-party data collection of customers. This new SaaS platform also unifies the native app experiences, customer journey orchestration and app UX experimentation with no-code approaches and intuitive visual UIs, freeing development teams to innovate market-differentiating app features.
Brett Caine, CEO and President at Airship, said : “Messaging only goes so far in helping to retain and monetise app users. Brands must provide valuable and relevant experiences in the moments people are engaged with the app to create reciprocal value exchanges necessary for sustained relationships .” He added: “With AXP, we’re giving brands unparalleled agility to grow user understanding and provide app experiences that reward customers for their loyalty .”
More than 15 leading brands gained early access to new AXP innovations such as AXP Mobile Data Hub, AXP Scenes, AXP Surveys and AXP Preference Center to evaluate and test the benefit to their businesses and provide feedback for ongoing refinement.
Joseph Brooks, Head of Product, Shell plc, one of Airship’s customers, said: “The Shell app is the centrepiece of our customers’ mobility experience, allowing them to pay and save in one easy step. With Airship’s real-time notifications and in-app automation we’ve increased our retention rate 3X and grown our active user base by 3.5X . The new capabilities in Airship’s App Experience Platform will help to dramatically accelerate our time-to-market and agility in optimising user onboarding and collecting in-app feedback from users to continue to improve their app experience .”
Michael Lowe, Vice President, Digital Strategy & Partnerships at NBC Sports Group, another of Airship’s customers, added: “Sports fans demand the best, most personalised in-the-moment app experiences, and it’s a requirement for our teams to look for opportunities for continued innovation that facilitates new user onboarding, drives new feature adoption, introduces new content franchises, and elicits valuable user feedback. Airship’s App Experience Platform provides us with new capabilities that save valuable product development time and give our team faster ways to optimise each fan’s journey .”
According to Forrester Research, Inc.’s, August 2021 report “Make Marketing More Than A Message ”: “The best brand experiences connect to customers in critical moments, not just at a channel level. Pulling off this level of personalisation requires that brands design for moments first … Marketers are innovating across critical facets of business (not just with media and messaging) by shaping the entire experience to differentiate their brand in the eyes of their customers .”
For the latest information on consumer privacy attitudes, preferences and behaviours, and how brands can create a trusted exchange with their customers, register for an April 14th webinar featuring guest speaker Stephanie Liu, Analyst, Forrester Research, Inc., and Mike Herrick, SVP of Technology, Airship.
For more detail on this announcement, please access ungated eBooks on MAX and AXP .
Additional Customer Quotes:
“Our entire team was both surprised and delighted by Airship’s new App Experience Platform ,” said Laurent Claramonte, head of data analytics for Products and Mobile Apps at Orange France . “With more than 10 apps in total, including TV, Smart Home and Messaging apps like Orange TV or Orange Mail, new capabilities like AXP Scenes free our developers to focus on new innovations as our product owners now have full autonomy to continually optimise native, multi-screen experiences that drive feature adoption. AXP is a game-changer, allowing us to go far beyond promotional and messaging-based approaches to drive better app onboarding and retention, and achieve greater customer satisfaction and loyalty .”
“As the most popular football media platform in the world, OneFootball is constantly adding new features, products and content to provide an immersive and fully personalised experience to more than 100 million football fans monthly ,” said Ismail Elshareef, Chief Product Officer at OneFootball . “With AXP Scenes and Surveys we can provide fans with better onboarding to these new experiences, collect more information upfront for greater personalization, and better inform future development to ensure our customers get exactly what they want from OneFootball .”
About Airship
No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship.
From the beginning of apps, Airship powered the first commercial messages and then expanded its data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation and feature release management. Now, with the Airship App Experience Platform (AXP), business users can create and adapt native app experiences on their own — with no ongoing developer support or app update required.
Having powered trillions of mobile app interactions for thousands of global brands, Airship’s technology and deep industry expertise have enabled apps to become the digital centre of customer experience, brand loyalty and monetisation.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406006111/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom